[go: up one dir, main page]

WO2002009743A1 - Methode de traitement d'un neoplasme - Google Patents

Methode de traitement d'un neoplasme Download PDF

Info

Publication number
WO2002009743A1
WO2002009743A1 PCT/US2001/022885 US0122885W WO0209743A1 WO 2002009743 A1 WO2002009743 A1 WO 2002009743A1 US 0122885 W US0122885 W US 0122885W WO 0209743 A1 WO0209743 A1 WO 0209743A1
Authority
WO
WIPO (PCT)
Prior art keywords
botulinum toxin
neoplasm
botulinum
type
toxin type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/022885
Other languages
English (en)
Inventor
Stephen Donovan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Sales LLC
Original Assignee
Allergan Sales LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
Priority to AU2001276005A priority Critical patent/AU2001276005A1/en
Publication of WO2002009743A1 publication Critical patent/WO2002009743A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to methods for treating neoplasms.
  • the present invention relates to methods for treating secretory neoplasms, both benign and cancerous, as well as hyperplasic chromaffin cells by local administration of a neurotoxin.
  • the adrenal or suprarenal glands are small, triangular-shaped structures located on top of the kidneys.
  • Each adrenal gland comprises an adrenal cortex or outer portion and an adrenal medulla or inner portion.
  • the cortex surrounds and encloses the medulla.
  • the adrenal cortex secretes the hormones cortisol and aldosterone.
  • Cortisol is produced during times of stress, regulates sugar usage, and is essential for maintenance of normal blood pressure.
  • Aldosterone is one of the main regulators of salt, potassium and water balance. If both adrenal glands are removed cortisol and aldosterone replacement therapy is mandatory.
  • the adrenal medulla secretes the catecholamines adrenalin (synonymously epinephrine) and noradrenalin (synonymously norepinephrine). These hormones are important for the normal regulation of a variety of bodily functions, including stress reaction, when they cause an increase in blood pressure, the pumping ability of the heart, and the level of blood sugar. Removal of the adrenal medulla results in little or no hormonal deficiency because other glands in the body can compensate. Contrarily, excessive catecholamine production can be life threatening.
  • the adrenal medulla can be viewed as a sympathetic ganglion innervated by preganglionic cholinergic nerve fibers. These nerve fibers release acetylcholine which causes secretion of catecholamines (primarily adrenaline) by a process of exocytosis from the chromaffin cells of the adrenal medulla.
  • catecholamines primarily adrenaline
  • the normal adrenal medulla is innervated by the splanchnic nerve, a preganglionic, cholinergic branch of the sympathetic nervous system. The activity of the adrenal medulla is almost entirely under such cholinergic nervous control.
  • Chromaffin cells including the chromaffin cells of the adrenal medulla
  • sympathetic ganglion cells have much in common as they are both derived from a common embryonic ancestor, the sympathagonium of the neural crest, as shown diagrammatically below. Examples of the types of neoplasms which can arise from each these cell types is shown in brackets. Each of the cell types shown can potentially secrete catecholamines.
  • a paraganglia (synonymously, chromaffin body) can be found in the heart, near the aorta, in the kidney, liver, gonads, and other places and is comprised of chromaffin cells which apparently originate from neural crest cells and which have migrated to a close association with autonomic nervous system ganglion cells.
  • a paraganglioma is a neoplasm comprised of chromaffin cells derived from a paraganglia.
  • a carotid body paraganglioma is referred to as a carotid paraganglioma, while an adrenal medulla paraganglioma is called a pheochromocytoma or a chromaffinoma.
  • the carotid body is often observed as a round, reddish-brown to tan structure found in the adventitia of the common carotid artery. It can be located on the posteromedial wall of the vessel at its bifurcation and is attached by ayer's ligament through which the feeding vessels run primarily from the external carotid. A normal carotid body measures 3-5 mm in diameter. Afferent innervation appears to be provided through the glossopharyngeal nerve (the ninth cranial nerve).
  • the glossopharyngeal nerve supplies motor fibers to the stylopharyngeus, parasympathetic secretomotor fibers to the parotid gland and sensory fibers to inter alia the tympanic cavity, interior surface of the soft palate and tonsils).
  • the carotid body includes Type I (chief) cells with copious cytoplasm and large round or oval nuclei.
  • the cytoplasm contains dense core granules that apparently store and release catecholamines.
  • the normal carotid body is responsible for detecting changes in the composition of arterial blood.
  • Carotid paragangliomas are rare tumors overall but are the most common form of head and neck paraganglioma.
  • the treatment of choice for most carotid body paragangliomas is surgical excision.
  • Tumor size is important because those greater than 5 cm in diameter have a markedly higher incidence of complications.
  • Perioperative alpha and beta adrenergic blockers are given (if the carotid paraganglioma is secreting catecholamines) or less preferably angiographic embolization preoperatively.
  • Radiotherapy either alone or in conjunction with surgery, is a second consideration and an area of some controversy.
  • paragangliomas, including carotid paragangliomas can be inoperable.
  • Pheochromocytomas occur in the adrenal medulla and cause clinical symptoms related to excess catecholamine production, including sudden high blood pressure (hypertension), headache, tachycardia, excessive sweating while at rest, the development of symptoms after suddenly rising from a bent-over position, and anxiety attacks. Abdominal imaging and 24 hour urine collection for catecholamines are usually sufficient for diagnosis. Catecholamine blockade with phenoxybenzamine and metyrosine generally ameliorates symptoms and is necessary to prevent hypertensive crisis during surgery, the current therapy of choice. Standard treatment is laparoscopic adrenalectomy, although partial adrenalectomy is often used for familial forms of pheochromocytoma. Malignant (cancerous) pheochromocytomas are rare tumors.
  • Pheochromocytomas have been estimated to be present in approximately 0.3% of patients undergoing evaluation for secondary causes of hypertension. Pheochromocytomas can be fatal if not diagnosed or if managed inappropriately. Autopsy series suggest that many pheochromocytomas are not clinically suspected and that the undiagnosed tumor is clearly associated with morbid consequences. The progression of changes in the adrenal medulla can be from normal adrenal medulla to adrenal medullary hyperplasia (a generalized increase in the number of cells and size of the adrenal medulla without the specific development of a tumor) to a tumor of the adrenal medulla (pheochromocytoma).
  • Treatment of a pheochromocytoma is surgical removal of one or both adrenal glands. Whether it is necessary to remove both adrenal glands will depend upon the extent of the disease. Patients who have had both adrenal glands removed must take daily cortisol and aldosterone replacement. Cortisol is replaced by either hydrocortisone, cortisone or prednisone and must be taken daily. Aldosterone is replaced by oral daily fludrocortisone (Florineftm). Increased amounts of replacement hydrocortisone or prednisone are required by such patients during periods of stress, including fever, cold, influenza, surgical procedure or anesthesia.
  • Glomus tumors are generally benign neoplasms, also arising from neuroectodermal tissues, found in various parts of the body. Glomus tumors are the most common benign tumors that arise within the temporal bone and fewer than five per cent of them become malignant and metastasize. Glomus tumors arise from glomus bodies distributed along parasympathetic nerves in the skull base, thorax and neck. There are typically three glomus bodies in each ear. The glomus bodies are usually found accompanying Jacobsen's (CN IX) or Arnold's (CN X) nerve or in the adventitia of the jugular bulb.
  • CN IX Jacobsen's
  • CN X Arnold's
  • the physical location is usually the mucosa of the promontory(glomus tympanicums), or the jugular bulb (glomus jugulare).
  • the incidence of glomus jugulare tumors is about 1 :1 ,300,000 population and the most striking bit of epidemiology is the predominant incidence in females with the female:male incidence ratio being at least 4:1.
  • Catecholamine secreting (i.e. functional) tumors occur in about 1% to 3% of cases.
  • Glomus tumors have the potential to secrete catecholamines, similar to the adrenal medulla which also arises from neural crest tissue and can also secrete catecholamines.
  • the neoplastic counterpart of a glomus tumor in the adrenal gland is the pheochromocytoma, and glomus tumors have been referred to as extra-adrenal pheochromocytoma.
  • Catecholamine secreting glomus tumors can cause arrhythmia, excessive perspiration, headache, nausea and pallor.
  • Glomus tumors can arise in different regions of the skull base. When confined to the middle ear space, they are termed glomus tympanicum. When arising in the region of the jugular foramen, regardless of their extent, they are termed glomus jugulare. When they arise high in the neck, extending towards the jugular foramen, they are termed glomus vagale. When they arise in the area of the carotid bifurcation, they are called carotid body tumors. Other known sites of glomus tumors include the larynx, orbit, nose, and the aortic arch.
  • Glomus Jugulare tumors are the most common tumors of the middle ear. These tumors tend to be very vascular and are fed by branches of the external carotid artery.
  • the symptoms of a glomus jugulare tumor include hearing loss with pulsatile ringing in the ear, dizziness, and sometimes ear pain.
  • the patient can have a hearing loss due possibly to blockage of the middle ear, but also there can be a loss of hearing due to nerve injury from the tumor mass.
  • Cranial nerve palsies of the nerves which control swallowing, gagging, shoulder shrugging and tongue movement can all be part of the presentation of glomus jugulare tumors. When the tympanic membrane is examined a red/blue pulsatile mass can often be seen.
  • Symptoms are insidious in onset. Because of the location and the vascular nature of the tumors, a most common complaint is pulsatile tinnitus. It is believed that the tinnitus is secondary to mechanical impingement on the umbo is most cases. Other common symptoms are aural fullness, and (conductive) hearing loss.
  • Treatment for a catecholamine secreting glomus tumor is irradiation and/or surgical ablation, preceded by administration of alpha and beta blockers.
  • Treatment for glomus jugulare tumors includes administration of alpha and beta blockers.
  • X-ray therapy can be used to improve symptoms even if the mass persists. It is also possible to embolize the tumor with materials which block its blood supply, however this procedure has associated problems with causing swelling of the tumor which can compress the brain stem and cerebellum as well as releasing the catecholamines from the cells which die when they lose their blood supply.
  • Surgery can be carried out upon small tumors appropriately located.
  • the complications of surgery for a glomus jugulare tumor are persistent leakage of cerebrospinal fluid from the ear and also palsy of one of the cranial nerves controlling face movement, sensation or hearing.
  • glomus jugulare tumors are somewhat problematic because they have a high recurrence rate and may require multiple operations.
  • Surgical ablation carries the risk of morbidity due mainly to iatrogenic cranial nerve deficits and CSF leaks. Lack of cranial nerve preservation is probably the most significant objection to surgical intervention because of the associated morbidity of lower cranial nerve deficits.
  • Radiotherapy also has serious complications, including osteoradionecrosis of the temporal bone, brain necrosis, pituitary- hypothalamic insufficiency, and secondary malignancy. Other postoperative complications include CSF leaks, aspiration syndromes, meningitis, pneumonia and wound infections.
  • Clostridium botulinum produces a potent polypeptide neurotoxin, botulinum toxin, which causes a neuroparalytic illness in humans and animals referred to as botulism.
  • the spores of Clostridium botulinum are found in soil and can grow in improperly sterilized and sealed food containers of home based canneries, which are the cause of many of the cases of botulism.
  • the effects of botulism typically appear 18 to 36 hours after eating the foodstuffs infected with a Clostridium botulinum culture or spores.
  • the botulinum toxin can apparently pass unattenuated through the lining of the gut and attack peripheral motor neurons. Symptoms of botulinum toxin intoxication can progress from difficulty walking, swallowing, and speaking to paralysis of the respiratory muscles and death.
  • Botulinum toxin type A is the most lethal natural biological agent known to man. About 50 picograms of botulinum toxin (purified neurotoxin complex) type A 1 is a LD 50 in mice. One unit (U) of botulinum toxin is defined as the LD5 0 upon intraperitoneal injection into female Swiss Webster mice weighing 18-20 grams each. Seven immunologically distinct botulinum neurotoxins have been characterized, these being respectively botulinum neurotoxin serotypes A, B, C-i, D, E, F and G each of which is distinguished by neutralization with type-specific antibodies. The different serotypes of botulinum toxin vary in the animal species that they affect and in the severity and duration of the paralysis they evoke.
  • botulinum toxin type A is 500 times more potent, as measured by the rate of paralysis produced in the rat, than is botulinum toxin type B.
  • botulinum toxin type B has been determined to be non-toxic in primates at a dose of 480 U/kg which is about 12 times the primate LD 50 for botulinum toxin type A.
  • Botulinum toxin apparently binds with high affinity to cholinergic motor neurons, is translocated into the neuron and blocks the release of acetylcholine.
  • Botulinum toxins have been used in clinical settings for the treatment of neuromuscular disorders characterized by hyperactive skeletal muscles.
  • Botulinum toxin type A has been approved by the U.S. Food and Drug Administration for the treatment of blepharospasm, strabismus and hemifacial spasm.
  • Non-type A botulinum toxin serotypes apparently have a lower potency and/or a shorter duration of activity as compared to botulinum toxin type A.
  • Clinical effects of peripheral intramuscular botulinum toxin type A are usually seen within one week of injection. The typical duration of symptomatic relief from a single intramuscular injection of botulinum toxin type A averages about three months.
  • botulinum toxins serotypes Although all the botulinum toxins serotypes apparently inhibit release of the neurotransmitter acetylcholine at the neuromuscular junction, they do so by affecting different neurosecretory proteins and/or cleaving these proteins at different sites.
  • botulinum types A and E both cleave the 25 kiloDalton (kD) synaptosomal associated protein (SNAP-25), but they target different amino acid sequences within this protein.
  • Botulinum toxin types B, D, F and G act on vesicle-associated protein (VAMP, also called synaptobrevin), with each serotype cleaving the protein at a different site.
  • VAMP vesicle-associated protein
  • botulinum toxin type Ci has been shown to cleave both syntaxin and SNAP-25.
  • action may affect the relative potency and/or duration of action of the various botulinum toxin serotypes.
  • the molecular weight of the botulinum toxin protein molecule, for all seven of the known botulinum toxin serotypes, is about 150 kD.
  • botulinum toxins are released by Clostridial bacterium as complexes comprising the 150 kD botulinum toxin protein molecule along with associated non-toxin proteins.
  • the botulinum toxin type A complex can be produced by Clostridial bacterium as 900 kD, 500 kD and 300 kD forms.
  • Botulinum toxin types B and Ci is apparently produced as only a 500 kD complex.
  • Botulinum toxin type D is produced as both 300 kD and 500 kD complexes.
  • botulinum toxin types E and F are produced as only approximately 300 kD complexes.
  • the complexes i.e.
  • molecular weight greater than about 150 kD are believed to contain a non- toxin hemaglutinin protein and a non-toxin and non-toxic nonhemaglutinin protein. These two non-toxin proteins (which along with the botulinum toxin molecule comprise the relevant neurotoxin complex) may act to provide stability against denaturation to the botulinum toxin molecule and protection against digestive acids when toxin is ingested. Additionally, it is possible that the larger (greater than about 150 kD molecular weight) botulinum toxin complexes may result in a slower rate of diffusion of the botulinum toxin away from a site of intramuscular injection of a botulinum toxin complex.
  • botulinum toxin inhibits potassium cation induced release of both acetylcholine and norepinephrine from primary cell cultures of brainstem tissue. Additionally, it has been reported that botulinum toxin inhibits the evoked release of both glycine and glutamate in primary cultures of spinal cord neurons and that in brain synaptosome preparations botulinum toxin inhibits the release of each of the neurotransmitters acetylcholine, dopamine, norepinephrine, CGRP and glutamate.
  • Botulinum toxin type A can be obtained by establishing and growing cultures of Clostridium botulinum in a fermenter and then harvesting and purifying the fermented mixture in accordance with known procedures. All the botulinum toxin serotypes are initially synthesized as inactive single chain proteins which must be cleaved or nicked by proteases to become neuroactive. The bacterial strains that make botulinum toxin serotypes A and G possess endogenous proteases and serotypes A and G can therefore be recovered from bacterial cultures in predominantly their active form. In contrast, botulinum toxin serotypes C-i, D and E are synthesized by nonproteolytic strains and are therefore typically unactivated when recovered from culture.
  • Serotypes B and F are produced by both proteolytic and nonproteolytic strains and therefore can be recovered in either the active or inactive form.
  • the proteolytic strains that produce, for example, the botulinum toxin type B serotype only cleave a portion of the toxin produced.
  • the exact proportion of nicked to unnicked molecules depends on the length of incubation and the temperature of the culture. Therefore, a certain percentage of any preparation of, for example, the botulinum toxin type B toxin is likely to be inactive, possibly accounting for the known significantly lower potency of botulinum toxin type B as compared to botulinum toxin type A.
  • botulinum toxin type B has, upon intramuscular injection, a shorter duration of activity and is also less potent than botulinum toxin type A at the same dose level. It has been reported that botulinum toxin type A has been used in clinical settings as follows:
  • BOTOX® BOTOX® per intramuscular injection (multiple muscles) to treat cervical dystonia
  • BOTOX® BOTOX® per intramuscular injection to treat glabellar lines (brow furrows) (5 units injected intramuscularly into the procerus muscle and 10 units injected intramuscularly into each corrugator supercilii muscle);
  • biceps brachii 50 U to 200 U.
  • Each of the five indicated muscles has been injected at the same treatment session, so that the patient receives from 90 U to 360 U of upper limb flexor muscle BOTOX® by intramuscular injection at each treatment session.
  • BOTOX ® and Dysport ® two commercially available botulinum type A preparations
  • preparations of botulinum toxins type B and F both obtained from Wako Chemicals, Japan
  • Botulinum toxin preparations were injected into the head of the right gastrocnemius muscle (0.5 to 200.0 units/kg) and muscle weakness was assessed using the mouse digit abduction scoring assay (DAS). ED 50 values were calculated from dose response curves. Additional mice were given intramuscular injections to determine LD 50 doses. The therapeutic index was calculated as LD50/ED 50 . Separate groups of mice received hind limb injections of BOTOX ® (5.0 to 10.0 units/kg) or botulinum toxin type B (50.0 to 400.0 units/kg), and were tested for muscle weakness and increased water consumption, the later being a putative model for dry mouth.
  • BOTOX ® 5.0 to 10.0 units/kg
  • botulinum toxin type B 50.0 to 400.0 units/kg
  • Antigenic potential was assessed by monthly intramuscular injections in rabbits (1.5 or 6.5 ng/kg for botulinum toxin type B or 0.15 ng/kg for BOTOX ® ). Peak muscle weakness and duration were dose related for all serotypes. DAS ED 50 values (units/kg) were as follows: BOTOX ® : 6.7, Dysport ® : 24.7, botulinum toxin type B: 27.0 to 244.0, botulinum toxin type F: 4.3. BOTOX ® had a longer duration of action than botulinum toxin type B or botulinum toxin type F.
  • Therapeutic index values were as follows: BOTOX ® : 10.5, Dysport ® : 6.3, botulinum toxin type B: 3.2. Water consumption was greater in mice injected with botulinum toxin type B than with BOTOX ® , although botulinum toxin type B was less effective at weakening muscles. After four months of injections 2 of 4 (where treated with 1.5 ng/kg) and 4 of 4 (where treated with 6.5 ng/kg) rabbits developed antibodies against botulinum toxin type B. In a separate study, 0 of 9 BOTOX ® treated rabbits demonstrated antibodies against botulinum toxin type A.
  • DAS results indicate relative peak potencies of botulinum toxin type A being equal to botulinum toxin type F, and botulinum toxin type F being greater than botulinum toxin type B.
  • botulinum toxin type A was greater than botulinum toxin type B
  • botulinum toxin type B duration of effect was greater than botulinum toxin type F.
  • the two commercial preparations of botulinum toxin type A (BOTOX ® and Dysport ® ) are different.
  • the increased water consumption behavior observed following hind limb injection of botulinum toxin type B indicates that clinically significant amounts of this serotype entered the murine systemic circulation.
  • the neurotransmitter acetylcholine is secreted by neurons in many areas of the brain, but specifically by the large pyramidal cells of the motor cortex, by several different neurons in the basal ganglia, by the motor neurons that innervate the skeletal muscles, by the preganglionic neurons of the autonomic nervous system (both sympathetic and parasympathetic), by the postganglionic neurons of the parasympathetic nervous system, and by some of the postganglionic neurons of the sympathetic nervous system.
  • acetylcholine has an excitatory effect.
  • acetylcholine is known to have inhibitory effects at some of the peripheral parasympathetic nerve endings, such as inhibition of the heart by the vagus nerves.
  • the efferent signals of the autonomic nervous system are transmitted to the body through either the sympathetic nervous system or the parasympathetic nervous system.
  • the preganglionic neurons of the sympathetic nervous system extend from preganglionic sympathetic neuron cell bodies located in the intermediolateral horn of the spinal cord.
  • the preganglionic sympathetic nerve fibers, extending from the cell body synapse with postganglionic neurons located in either a paravertebral sympathetic ganglion or in a prevertebral ganglion. Since, the preganglionic neurons of both the sympathetic and parasympathetic nervous system are cholinergic, application of acetylcholine to the ganglia will excite both sympathetic and parasympathetic postganglionic neurons.
  • Acetylcholine activates two types of receptors, muscarinic and nicotinic receptors.
  • the muscarinic receptors are found in all effector cells stimulated by the postganglionic neurons of the parasympathetic nervous system, as well as in those stimulated by the postganglionic cholinergic neurons of the sympathetic nervous system.
  • the nicotinic receptors are found in the synapses between the preganglionic and postganglionic neurons of both the sympathetic and parasympathetic.
  • the nicotinic receptors are also present in many membranes of skeletal muscle fibers at the neuromuscular junction.
  • Acetylcholine is released from cholinergic neurons when small, clear, intracellular vesicles fuse with the presynaptic neuronal cell membrane.
  • a wide variety of non-neuronal secretory cells such as, adrenal medulla (as well as the PC12 cell line) and pancreatic islet cells release catecholamines and insulin, respectively, from large dense-core vesicles.
  • the PC12 cell line is a clone of rat pheochromocytoma cells extensively used as a tissue culture model for studies of sympathoadrenal development.
  • Botulinum toxin inhibits the release of both types of compounds from both types of cells in vitro, permeabilized (as by electroporation) or by direct injection of the toxin into the denervated cell. Botulinum toxin is also known to block release of the neurotransmitter glutamate from cortical synaptosomes cell cultures.
  • neoplasms such as hyperplasic and/or neoplasmic, catecholamine secreting chromaffin cells, including paragangliomas, such as glomus tumors.
  • the present invention meets this need and provides an effective, non- surgical ablation, non-radiotherapy therapeutic method for treating a various neoplasm, including paragangliomas, such as glomus tumors.
  • the present invention includes within its scope a method for treating a neoplasm by local administration of between about 10 "3 U/kg and about 2000 U/kg of a botulinum toxin to the neoplasm, thereby treating the neoplasm by either reducing the size of the neoplasm and/or by reducing a secretion from the neoplasm.
  • a method according to the present invention can be carried out by direct injection of a botulinum toxin into the body of a neoplasm or by implantation of a botulinum toxin implant into or onto the body of the neoplasm.
  • a method within the scope of the present invention can be practiced to locally administer between about 10 "3 U/kg and about 2000 U/kg of a botulinum toxin to a neoplasm.
  • U/kg means units of a botulinum toxin per kilogram of total patient weight.
  • the botulinum toxin can be one of the botulinum toxin types A, B, d, D, E, F and G, and is preferably a botulinum toxin type A because of the known clinical efficacy of botulinum toxin type A for a number of indications and because of its ready availability.
  • the botulinum toxin is administered in an amount of between about 1 U and about 40,000 U (total units, not per kg of patient weight).
  • the amount of botulinum toxin administered i.e. 40,000 units
  • Suitable controlled release delivery systems to use in the present invention for either the continuous or pulsatile intra or peri-neoplasm release of therapeutic amounts of a botulinum toxin are disclosed in co-pending applications serial number 09/587250 entitled “Neurotoxin Implant” and in the U.S. application filed July 21 , 2000 entitled “Botulinum Toxin Implant", serial number pending.
  • the amount of a botulinum toxin type A locally administered to the body of or to a site within the body of the neoplasm according to the present invention can be an amount between about 10 "3 U/kg and about 40 U/kg. Less than about 10 "3 U/kg of a botulinum toxin type A is not expected to result in a significant therapeutic efficacy, while more than about 40 U/kg of a botulinum toxin type A can be expected to result in a toxic or near toxic dose of the toxin.
  • the amount of a botulinum toxin type B locally administered to the neoplasm according to the present invention can be an amount between about 10 "3 U/kg and about 2000 U/kg. Less than about 10 "3 U/kg of a botulinum toxin type B is not expected to result in a significant therapeutic efficacy, while more than about 2000 U/kg of a botulinum toxin type B can be expected to result in a toxic or near toxic dose of the type B toxin. It has been reported that about 2000 units/kg, intramuscular, of a commercially available botulinum toxin type B preparation approaches a primate lethal dose of type B botulinum toxin.
  • botulinum toxins types C, D, E, F and G amounts for injection into a neoplasm can be determined on a patient by patient basis and are not expected to exceed the type B toxin dose range.
  • the amount of a type A botulinum toxin administered according to the disclosed methods is between about 10 "2 U/kg and about 25 U/kg.
  • the amount of a type B botulinum toxin administered by a continuous release system during a given period is between about 10 "2 U/kg and about 1000 U/kg, since it has been reported that less than about 1000 U/kg of type B botulinum toxin can be intramuscularly administered to a primate without systemic effect. Ibid.
  • the type A botulinum toxin is administered in an amount of between about 10 "1 U/kg and about 15 U/kg.
  • the type A botulinum toxin is administered in an amount of between about 1 U/kg and about 10 U/kg.
  • an intraneoplastic administration of from about 1 units to less than about 100 units of a botulinum toxin type A can provide effective and long lasting therapeutic relief, as set forth herein. More preferably, from about 5 units to about 75 units of a botulinum toxin, such as a botulinum toxin type A, can be used and most preferably, from about 5 units to about 50 units of a botulinum . toxin type A, can be locally administered into a target neoplasm tissue with efficacious results.
  • a botulinum toxin such as botulinum toxin type A
  • a botulinum toxin can be locally administered to a neoplasm target tissue with therapeutically effective results, as described herein.
  • a detailed method within the scope of the present invention can be carried out by local administration of between about 10 "3 U/kg and about 2000 U/kg of a botulinum toxin type A to a neoplasm of a human patient, thereby reducing a secretion from the neoplasm.
  • the secretion can be a catecholamine secretion.
  • the present invention also includes a method for treating a functional neoplasm or functional chromaffin body by local administration of a neurotoxin to a neoplasm thereby reducing a catecholamine secretion from the neoplasm.
  • functional means secreting a catecholamine
  • local administration means direct injection of the neurotoxin into or to the local area of the neoplasm
  • neoplasm or synonymously "tumor”
  • systemic routes of administration such as oral and intravenous routes of administration, are excluded from the scope of the present invention.
  • the functional neoplasm treated can be a paraganglioma or a glomus tumor.
  • the botulinum toxin can be a modified botulinum toxin, that is the botulinum toxin can have at least one of its amino acids deleted, modified or replaced, as compared to a native botulinum toxin.
  • the botulinum toxin can be a recombinant produced botulinum toxin or a derivative or fragment thereof.
  • a preferred method for treating a secretory neoplasm can have the step of local administration of a therapeutic amount of a botulinum toxin to a secretory neoplasm of a human patient, thereby reducing a secretion from the neoplasm.
  • the secretion is a catecholamine secretion and the secretory tumor can be a functional paraganglioma.
  • the functional paraganglioma can be, for example, a glomus tympanicum, a glomus jugulare, glomus vagale and a carotid body tumor.
  • the present invention also includes a method for improving patient function, the method comprising the step of administering a neurotoxin to a functional paraganglioma of a human patient, thereby improving patient function as determined by improvement in one or more of the factors of reduced pain, reduced time spent in bed, increased ambulation, healthier attitude and a more varied lifestyle.
  • a further method within the scope of the present invention for treating a secretion of a patient can have the step of administering to the patient an effective amount of a botulinum toxin in order to reduce the secretion, wherein the secretion is a catecholamine secretion.
  • the secretion can be an endocrine secretion from a chromaffin cell.
  • the chromaffin cell can be a hyperplasic and/or hypertonic chromaffin cell and the secretion can be a cholinergic influenced secretion.
  • An additional method within the scope of the present invention can be a method for treating a cholinergic influenced, endocrine, catecholamine chromaffin cell secretion of a human patient by administering to a human patient a therapeutically effective amount of botulinum toxin type A in order to reduce the secretion.
  • the present invention also includes a method for treating a gland by administering to a gland a botulinum toxin thereby reducing a secretory activity of the gland, wherein the gland is a catecholamine secreting gland.
  • the gland can be an excessively secreting gland and/or the gland can be influenced by the cholinergic nervous system.
  • the botulinum toxin can be administered by injection into the gland or into the local area of the gland.
  • Another preferred method within the scope of the present invention is a method for treating an excessively catecholamine secreting gland, the method comprising the step of injecting an excessively catecholamine secreting, cholinergic nervous system influenced gland or local gland area of a human patient with a therapeutically effective amount of botulinum toxin type A in order to reduce the excessive catecholamine secretion.
  • the invention also includes a method for treating an endocrine disorder, the method comprising the step of administering a neurotoxin to a mammal, thereby reducing an excessive secretion of an endocrine gland.
  • the invention encompasses a method for treating an adrenal disorder, the method comprising the step of administering a neurotoxin to an adrenal gland of a mammal, thereby reducing an excessive secretion of an adrenal gland.
  • the present invention also includes within its scope a method for treating a neoplasm, the method comprising the step of local administration of a botulinum toxin to a neoplasm or to the vicinity of the neoplasm, thereby causing a reduction in the size of the neoplasm.
  • the neoplasm can be a paraganglioma and the diameter of the neoplasm can be reduced by between about 20% and about 100% subsequent to the local administration of the botulinum toxin.
  • the present invention is based upon the discovery that the size and/or a secretory activity of a wide variety of neoplasms can be reduced by treatment with a botulinum toxin. Additionally, excessively secreting chromaffin cells and chromaffin bodies can be treated in vivo with a botulinum toxin to reduce the secretory activity.
  • the target tissue is cholinergically innervated or susceptible to high toxin dosing such that the proteolytic light chain of the toxin is internalized by a cholinergic neuron which influences the activity of a neoplasm, such as a chromaffin cell and/or by a target secretory chromaffin cell.
  • cholinergically innervated functional paragangliomas, pheochromocytomas and glomus tumors can be treated by local administration of a neurotoxin, such as a botulinum toxin.
  • a neurotoxin such as a botulinum toxin.
  • local administration it is meant that the neurotoxin is administered directly to, into, or to the vicinity of, the tumor or local tumor area to be treated.
  • Local administration includes intratumor injection of a neurotoxin.
  • Non-cancerous (benign), cancerous (malignant) hyperplasic and/or hypertonic catecholamine secreting tissues can be treated by a method within the scope of the present invention. Nodular or diffuse hyperplasia which precedes pheochromocytoma can also be treated by the present method.
  • botulinum injection can be used to reduce catecholamine secretion by hyperplasic, cholinergically innervated chromaffin cells.
  • botulinum toxin a particular neurotoxin, botulinum toxin
  • a single administration of the botulinum toxin can substantially reduces the tachycardia, headache, hypertension, and other catecholamine excess symptoms which can accompany a functional paraganglioma.
  • the route of administration and amount of botulinum toxin administered can vary widely according to the particular oncologic disorder being treated and various patient variables including size, weight, age, disease severity and responsiveness to therapy. Method for determining the appropriate route of administration and dosage are generally determined on a case by case basis by the attending physician. Such determinations are routine to one of ordinary skill in the art (see for example, Harrison's Principles of Internal Medicine (1997), edited by Anthony Fauci et al., 14 th edition, published by McGraw Hill).
  • a solution of botulinum toxin type A complex can be endoscopically administered intramuscular directly to the tumor, thereby substantially avoiding entry of the toxin into the systemic circulation.
  • the specific dosage appropriate for administration is readily determined by one of ordinary skill in the art according to the factor discussed above.
  • the dosage can also depend upon the size of the tumor to be treated or denervated, and the commercial preparation of the toxin. Additionally, the estimates for appropriate dosages in humans can be extrapolated from determinations of the amounts of botulinum required for effective denervation of other non-neoplastic tissues. Thus, the amount of botulinum A to be injected is proportional to the mass and level of activity of the neoplasm to be treated.
  • a botulinum toxin such as botulinum toxin type A
  • a botulinum toxin can be administered to effectively accomplish a toxin induced neoplastic atrophy upon administration of the neurotoxin at or to the vicinity of the neoplasm.
  • Less than about 0.01 U/kg of a botulinum toxin does not have a significant therapeutic effect upon a functional (i.e. catecholamine secreting) neoplasm, while more than about 2000 U/kg or 35 U/kg of a botulinum toxin B or A, respectively, approaches a toxic dose of the specified botulinum toxin.
  • a more preferred dose range to a functional paraganglioma is from about 0.01 U/kg to about 25 U/kg of a botulinum toxin, such as that formulated as BOTOX®.
  • the actual amount of U/kg of a botulinum toxin to be administered depends upon factors such as the extent (mass) and level of activity of the neoplasm to be treated and the administration route chosen.
  • Botulinum toxin type A is a preferred botulinum toxin serotype for use in the methods of the present invention.
  • botulinum toxin The main site of action of botulinum toxin is the neuromuscular junction where the toxin binds rapidly and prevents the release of acetylcholine.
  • botulinum toxins have a known binding affinity for cholinergic, pre-synaptic, peripheral motor neurons
  • the botulinum toxins can also bind to and translocate into a wide variety of non-neuronal secretory cells, where the toxin then acts, in the known manner, as an endoprotease upon its respective secretory vessel-membrane docking protein.
  • the toxin is preferably injected into secretory or glandular tissues to provide a high local concentration of the toxin.
  • the present invention is applicable to the treatment of secretory, including catecholamine secreting, chromaffin cells and tumors located throughout the body, including secretory tumors with little or no cholinergic innervation.
  • a neurotoxin used to practice a method within the scope of the present invention is a botulinum toxin, such as one of the serotype A, B, C, D, E, F or G botulinum toxins.
  • the botulinum toxin used is botulinum toxin type A, because of its high potency in humans, ready availability, and known use for the treatment of skeletal and smooth muscle disorders when locally administered by intramuscular injection.
  • a route for administration of a neurotoxin according to the present disclosed invention for treating a cancer can be selected based upon criteria such as the solubility characteristics of the neurotoxin toxin chosen as well as the amount of the neurotoxin to be administered.
  • the amount of the neurotoxin administered can vary widely according to the particular disorder being treated, its severity and other various patient variables including size, weight, age, and responsiveness to therapy. For example, the extent of the neoplasm influenced is believed to be proportional to the volume of neurotoxin injected, while the quantity of the denervation is, for most dose ranges, believed to be proportional to the concentration of neurotoxin injected.
  • Methods for determining the appropriate route of administration and dosage are generally determined on a case by case basis by the attending physician. Such determinations are routine to one of ordinary skill in the art (see for example, Harrison's Principles of Internal Medicine (1997), edited by Anthony Fauci et al., 14th edition, published by McGraw Hill).
  • the present invention includes within its scope the use of any neurotoxin which has a long duration therapeutic effect when locally applied to a functioning paraganglioma of a patient.
  • neurotoxins made by any of the species of the toxin producing Clostridium bacteria, such as Clostridium botulinum, Clostridium butyricum, and Clostridium beratti can be used or adapted for use in the methods of the present invention.
  • all of the botulinum serotypes A, B, C, D, E , F and G can be advantageously used in the practice of the present invention, although type A is the most preferred serotype, as explained above.
  • Practice of the present invention can provide neoplasmic atrophy and remission for 27 months or longer in humans.
  • botulinum toxin type B It is known that catecholamine release from permeabilized adrenal medulla cells can be inhibited by a botulinum toxin. Additionally, it is known that release of insulin from permeabilized (as by electroporation) insulin secreting cells can be inhibited by a botulinum toxin.
  • the cell membranes of these non-nerve cells can be permeabilized to assist introduction of a botulinum toxin into the cell's cytosol due to the lack of cell surface receptors for a botulinum toxin.
  • botulinum toxin type B apparently inhibits insulin secretion by cleaving synaptobrevin present in the insulin secreting cell line HIT-15.
  • the intracellular protein SNAP-25 is widely distributed in both neuronal and non-neuronal secretory cells and botulinum toxin type A is an endopeptidase for which the specific substrate is SNAP- 25.
  • botulinum toxin type A is an endopeptidase for which the specific substrate is SNAP- 25.
  • cholinergic neurons have a high affinity acceptor for the botulinum and tetanus toxins (and are therefore more sensitive than other neurons and other cells to the inhibition of vesicle mediated exocytosis of secretory compounds)
  • the toxin concentration is raised, non-cholinergic sympathetic neurons, chromaffin cells and other cell types can take up a botulinum toxin and show reduced exocytosis.
  • non-cholinergic nerve fibers as well as non or poorly innervated secretory neoplasms can be treated by use of an appropriately higher concentration of a botulinum toxin to bring about therapeutic atrophy of secretory neoplasms (i.e. treatment of functional (catecholamine secreting) paragangliomas) and hyperplasic chromaffin cells.
  • the catecholamine secretion rate is controlled by the activity of the nerves stimulating the chromaffin cells. Contrary to the general belief that the pheochromocytomas are not innervated and that the release of catecholamines from such tumors is not under nervous control, there is evidence for cholinergic innervation of such tumors. For example, electron microscopy has demonstrated a nerve with small synaptic vesicles in contact with cells containing catecholamine vesicles. Additionally, the sudden secretion of catecholamines from a pheochromocytomas into the circulation precipitated by an emotional upset, hypotension or hyperventilation points to a nervous system influence on the secretion.
  • a method within the scope of the present invention can provide improved patient function.
  • "Improved patient function” can be defined as an improvement measured by factors such as a reduced pain, reduced time spent in bed, increased ambulation, healthier attitude, more varied lifestyle and/or healing permitted by normal muscle tone.
  • Improved patient function is synonymous with an improved quality of life (QOL).
  • QOL can be assesses using, for example, the known SF-12 or SF-36 health survey scoring procedures.
  • SF-36 assesses a patient's physical and mental health in the eight domains of physical functioning, role limitations due to physical problems, social functioning, bodily pain, general mental health, role limitations due to emotional problems, vitality, and general health perceptions. Scores obtained can be compared to published values available for various general and patient populations.
  • the present invention is practiced by direct injection into the neoplasm or to the local area of the neoplasm of botulinum toxin type A. It has been reported that at the neuroglandular junction, the chemical denervation effect of a botulinum toxin, such as botulinum toxin type A, has a considerably longer duration of action, i.e. 27 months vs. 3 months.
  • the present invention does include within its scope: (a) neurotoxin complex as well as pure neurotoxin obtained or processed by bacterial culturing, toxin extraction, concentration, preservation, freeze drying and/or reconstitution and; (b) modified or recombinant neurotoxin, that is neurotoxin that has had one or more amino acids or amino acid sequences deliberately deleted, modified or replaced by known chemical/biochemical amino acid modification procedures or by use of known host cell/recombinant vector recombinant technologies, as well as derivatives or fragments of neurotoxins so made, and includes neurotoxins with one or more attached targeting moieties for chromaffin and neoplasm cells types.
  • Botulinum toxins for use according to the present invention can be stored in lyophilized or vacuum dried form in containers under vacuum pressure. Prior to lyophilization the botulinum toxin can be combined with pharmaceutically acceptable excipients, stabilizers and/or carriers, such as albumin. The lyophilized or vacuum dried material can be reconstituted with saline or water.
  • One or two port endoscopy of the middle ear can be carried out.
  • anatomical structures can be visualized by transmeatal or transtympanic rigid scopes of different angles and by a flexible scope in the eustachian tube.
  • Three endoscopic routes to the middle ear can be used, these being: (1) transmeatal after raising a tympanomeatal flap, (2) transtympanic through a tympanic incision, and (3) the non-invasive through the preformed channel of the eustachian tube.
  • a transtympanic endoscope can be used to view of the tympanic cavity.
  • a flexible, steerable scope with an outside diameter of 0.8 mm (12,000 pixels; angle of view, 70°; total length, 650 mm; deflection angle, 90°; and length of deflectable part 25 mm) obtained from Micromed Co, Dornbirn, Austria can be used for transtubal endoscopy.
  • the patient's head can be positioned in 30° lateral decubitus.
  • the transtubal scope can be introduced through a tubal catheter placed at the pharyngeal orifice of the eustachian tube under endoscopic guidance (rigid 70° scope) through the contralateral nasal airway. After removing the rigid scope, the flexible steerable scope can be advanced into the middle ear through the tubal catheter. Successful advancement of the scope to the middle ear requires an adequate width of the tubal isthmus (mean, 1.0 mm wide and 2 mm high).
  • Transmeatal or transtympanic endoscopy can be performed using a rigid scope.
  • the outside diameter of the scope can be either 2.3 or 1.9 mm, with angles of 0°, 30°, or 70° (Karl Storz, Tuttlingen, and Aesculap).
  • the tympanic cavity can be opened by endoscopically raising a tympanomeatal flap so that the scope can enter the posterior part of the cavity below the incudostapedial joint.
  • radial incisions can be made in the tympanic membrane either between the posterosuperior and the posteroinferior quadrant or in the anteroinferior quadrant, depending on the region of interest.
  • Images can be recorded on a digital image recording device from S-VHS video sources (Digi-Still Unit and S- VHS Video Recorder; Sony, Vienna, Austria).
  • the field of view available depends on the angle of the scope (0°, 30°, or 70°).
  • the 0° scopes can provide visualization only of the long process of the incus and the medial wall (labyrinthine wall).
  • the 30° scopes can afford a larger view in all directions.
  • the field of view can extend to the facial canal with the scope directed upward, to the round window niche with the scope directed downward, to the tympanic sinus with the scope directed posteriorly, and to the cochleariform process with the scope directed anteriorly.
  • the 70° scope can offer an even wider view of the tympanic cavity.
  • the tympanic chord and the aditus ad antrum can be seen above, the hypotympanum below, the lateral sinus and facial recess posteriorly, and the tympanic orifice of the tube anteriorly.
  • the isthmus can be successfully negotiated and passage aided by subtly maneuvering and turning the scope tip.
  • the steerable scope Once the steerable scope has reached the protympanum, it can be advanced along 2 alternative routes: (1 ) above the tensor tendon into the epitympanum and then along the tegmen to the mastoid antrum; or (2) below the tensor tendon into the mesotympanum toward the incudostapedial joint and then either (a) medial to the incus and above the stapes into the aditus ad antrum or (b) lateral to the incus toward the tympanic chord or (c) below the stapes toward the lateral sinus.
  • the scope As the scope is advanced through the mesotympanum, it passes the entire tympanic membrane, which forms the lateral wall and can be inspected in its entire extension. Along the routes described, the flexible scope can be easily maneuvered past the ossicles without injuring them.
  • the specific amount of BOTOX® administered depends upon a variety of factors to be weighed and considered within the discretion of the attending physician and in each of the examples insignificant amounts of botulinum toxin appear systemically with no significant side effects.
  • a female patient, aged 58 presents with tachycardia, headache and elevated urine catecholamines metabolites.
  • Adrenal function is normal.
  • a benign, functional, middle ear glomus tumor is identified and is treated by endoscopic injection of from 10 unit to 100 units of BOTOX ® into the tumor mass.
  • serum catecholamines return to normal and remain so for the ensuing 2 to 24 months.
  • glomus tumors which have arisen from glomus bodies distributed along parasympathetic nerves in the skull base, thorax and neck can be likewise treated.
  • a 44 year old male patient with a neck mass is examined and a diagnosis of carotid paraganglioma is made.
  • the carotid paraganglioma is dark, tan to purple in color and is fairly well circumscribed with a very thin fibrous capsule, presented as a non-tender neck mass located just anterior to the sternocleidomastoid muscle at the level of the hyoid.
  • the patient shows symptoms associated with catecholamine production, such as fluctuating hypertension, blushing and palpitations. Screening for urinary metanephrines and serum catecholamines is positive. Perioperative alpha and beta adrenergic blockers are given.
  • the approach is transcervical and from 10 unit to 150 units of BOTOX ® is injected into the mass of the tumor which is in proximity to or innervated by the glossopharyngeal nerve.
  • serum catecholamines return to normal and remain so for the ensuing 2 to 27 months.
  • a 62 year old female is admitted with symptoms of excessive catecholamine production, including tachycardia and hypertension.
  • the patient abstains from bananas, vanilla, coffee, tea, cocoa, chocolate, cola beverages, or medications such as tranquilizers and nose sprays for colds for 2 days.
  • Measurement of adrenalin and noradrenalin breakdown products in blood and a 24-hour collection of urine confirms the existence of an excessive catecholamine secretion.
  • a computerized tomographic scan (CT or MRI to provide a 3-dimensional picture of the adrenal gland), or a nuclear medicine scan is carried out to attempt determination of the location and size of the tumor.
  • Biopsy reveals a precancerous, hyperplasic adrenal medulla. From 10 to 150 units of BOTOX ® is injected endoscopically directly into the adrenal medulla. Within 1-7 days serum catecholamines return to normal and remain so for the ensuing 2 to 24 months.
  • a 24 year old female presents with a history of tachycardia and hypertension.
  • a diagnosis of paraganglioma is made.
  • 30 units of BOTOX ® is injected directly into the tumor.
  • Within 1 to 7 days the tachycardia and hypertension has been substantially alleviated and the patient remains asymptomatic thereafter. Radiography and at 3 months post injection fails to reveal any evidence of the neoplasm.
  • a 42 year old female presents with a history of tachycardia and hypertension.
  • a diagnosis of paraganglioma is made.
  • 1500 units of a botulinum type B preparation is injected directly into the tumor.
  • the tachycardia and hypertension has been substantially alleviated and the patient remains asymptomatic thereafter.
  • Radiography and biopsy at 3 months post injection fails to reveal any evidence of the neoplasm.
  • a 58 year old female is diagnosed with a paraganglioma. Between about 10 "3 U/kg and about 35 U/kg of a botulinum toxin type C preparation (for example between about 10 units and about 10,000 units of a botulinum type C preparation) is injected directly into the tumor. Within 1 to 7 days the tachycardia and hypertensive symptoms are been substantially alleviated and the patient remains asymptomatic. Radiography and biopsy at 3 months post injection fails to reveal any evidence of the neoplasm.
  • a 56 year old obese female is diagnosed with paraganglioma.
  • a botulinum toxin type D preparation for example between about 10 units and about 10,000 units of a botulinum type D preparation
  • a botulinum toxin type D preparation for example between about 10 units and about 10,000 units of a botulinum type D preparation
  • Radiography and biopsy at 3 months post injection fails to reveal any evidence of the neoplasm.
  • a 61 year old female is diagnosed with paraganglioma. Between about 10 "3 U/kg and about 35 U/kg of a botulinum toxin type E preparation (for example between about 10 units and about 10,000 units of a botulinum type E preparation) is injected directly into the tumor. Within 1 to 7 days the tachycardia and hypertensive symptoms have been substantially alleviated and the patient remains asymptomatic. Radiography and biopsy at 3 months post injection fails to reveal any evidence of the neoplasm.
  • a 52 year old male is diagnosed with paraganglioma.
  • a botulinum toxin type F preparation for example between about 10 units and about 10,000 units of a botulinum type F preparation
  • a botulinum toxin type F preparation for example between about 10 units and about 10,000 units of a botulinum type F preparation
  • Radiography and biopsy at 3 months post injection fails to reveal any evidence of the neoplasm.
  • Example 11 Treatment of a Neoplasm With Botulinum Toxin Type G
  • a 14 year old male is diagnosed with paraganglioma.
  • a botulinum toxin type G preparation for example between about 10 units and about 10,000 units of a botulinum type G preparation
  • a botulinum toxin type G preparation for example between about 10 units and about 10,000 units of a botulinum type G preparation
  • Radiography and biopsy at 3 months post injection fails to reveal any evidence of the neoplasm.
  • the invention renders unnecessary many surgical procedures for effective treatment of functioning chromaffin bodies, including hyperplasic, hypertonic and neoplasmic catecholamine secreting tissues.
  • the ameliorative effects of the present invention can persists for two years or longer from a single local administration of a neurotoxin as set forth herein.
  • the present invention includes local otic administration methods wherein two or more neurotoxins, such as two or more botulinum toxins, are administered concurrently or consecutively.
  • two or more neurotoxins such as two or more botulinum toxins
  • botulinum toxin type A can be administered until a loss of clinical response or neutralizing antibodies develop, followed by administration of botulinum toxin type E.
  • a combination of any two or more of the botulinum serotypes A-G can be locally administered to control the onset and duration of the desired therapeutic result.
  • non-neurotoxin compounds can be administered prior to, concurrently with or subsequent to administration of the neurotoxin to proved adjunct effect such as enhanced or a more rapid onset of denervation before the neurotoxin, such as a botulinum toxin, begins to exert its therapeutic effect.
  • My invention also includes within its scope the use of a neurotoxin, such as a botulinum toxin, in the preparation of a medicament for the treatment of a functioning chromaffin body disorder by local administration of the neurotoxin.
  • a neurotoxin such as a botulinum toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une méthode de traitement d'un néoplasme par administration locale d'une toxine botulinique au niveau du néoplasme, ladite méthode permettant de réduire la taille et/ou l'activité sécrétoire du néoplasme.
PCT/US2001/022885 2000-08-02 2001-07-20 Methode de traitement d'un neoplasme Ceased WO2002009743A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001276005A AU2001276005A1 (en) 2000-08-02 2001-07-20 Method for treating a neoplasm

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63122100A 2000-08-02 2000-08-02
US09/631,221 2000-08-02

Publications (1)

Publication Number Publication Date
WO2002009743A1 true WO2002009743A1 (fr) 2002-02-07

Family

ID=24530276

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/022885 Ceased WO2002009743A1 (fr) 2000-08-02 2001-07-20 Methode de traitement d'un neoplasme

Country Status (4)

Country Link
AR (1) AR030104A1 (fr)
AU (1) AU2001276005A1 (fr)
TW (1) TWI300717B (fr)
WO (1) WO2002009743A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071525A1 (fr) * 2002-02-08 2004-08-26 Allergan, Inc. Methodes de traitement de troubles des glandes mammaires
JP2006519260A (ja) * 2003-03-03 2006-08-24 アラーガン、インコーポレイテッド 子宮障害を処置するためのクロストリジウム神経毒
US7709440B2 (en) 2004-09-23 2010-05-04 Toxcure, Inc. Treating neoplasms with neurotoxin
WO2010055358A1 (fr) 2008-11-17 2010-05-20 Syntaxin Limited Suppression de cancers
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
RU2464937C1 (ru) * 2011-05-17 2012-10-27 Федеральное государственное учреждение "Санкт-Петербургский научно-исследовательский институт уха, горла, носа и речи" Министерства здравоохранения и социального развития России (СПб НИИ ЛОР МИНЗДРАВСОЦРАЗВИТИЯ РОССИИ) Способ удаления параганглиомы латерального основания черепа отиатрической формы
US8343929B2 (en) 2004-09-23 2013-01-01 Toxcure, Inc. Treating neoplasms with neurotoxin
US8530410B2 (en) 2004-04-02 2013-09-10 Allergan, Inc. Method for treating a keloid with a botulinum toxin
RU2615119C1 (ru) * 2016-05-23 2017-04-03 государственное бюджетное образовательное учреждение высшего профессионального образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ хирургического лечения тимпанального гломуса
US10076557B2 (en) 2003-12-09 2018-09-18 Allergan, Inc. Botulinum toxin therapy for skin disorders
US10466245B2 (en) 2008-02-20 2019-11-05 The Secretary Of State For Health Covalently linked thermostable kinase for decontamination process validation
RU2769917C1 (ru) * 2021-02-24 2022-04-08 федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ хирургического лечения объемных образований среднего уха

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017904A2 (fr) * 1993-12-28 1995-07-06 Allergan Toxines botulinum utilisees dans le traitement de divers troubles, et douleurs associees
US5466672A (en) * 1992-12-04 1995-11-14 Ophidian Pharmaceuticals, Inc. Therapeutic use of clostridium difficile toxin A
WO2001041790A1 (fr) * 1999-12-07 2001-06-14 Allergan Sales, Inc. Toxine botulinique permettant la reduction de la secretion de catecholamine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466672A (en) * 1992-12-04 1995-11-14 Ophidian Pharmaceuticals, Inc. Therapeutic use of clostridium difficile toxin A
WO1995017904A2 (fr) * 1993-12-28 1995-07-06 Allergan Toxines botulinum utilisees dans le traitement de divers troubles, et douleurs associees
WO2001041790A1 (fr) * 1999-12-07 2001-06-14 Allergan Sales, Inc. Toxine botulinique permettant la reduction de la secretion de catecholamine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MUNCHAU A & BHATIA K P: "Uses of botulinum toxin injection in medicine today.", BRITISH MEDICAL JOURNAL, vol. 319, no. 7228, 15 January 2000 (2000-01-15), pages 161 - 165, XP002182213 *
SCHANTZ E J & JOHNSON E A: "Properties and use of botulinum toxin and other microbial neurotoxins in medicine", MICROBIOLOGICAL REVIEWS, vol. 56, no. 1, 1 March 1992 (1992-03-01), pages 80 - 99, XP000569909 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838007B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US7846456B2 (en) 1999-12-07 2010-12-07 Allergan, Inc. Methods for breast treatment
WO2004071525A1 (fr) * 2002-02-08 2004-08-26 Allergan, Inc. Methodes de traitement de troubles des glandes mammaires
JP2006510723A (ja) * 2002-02-08 2006-03-30 アラーガン、インコーポレイテッド 乳腺障害の処置方法
EP1728517A3 (fr) * 2002-02-08 2008-06-25 Allergan, Inc. Methodes de traitement de troubles des glandes mammaires
JP2006519260A (ja) * 2003-03-03 2006-08-24 アラーガン、インコーポレイテッド 子宮障害を処置するためのクロストリジウム神経毒
JP2012082231A (ja) * 2003-03-03 2012-04-26 Allergan Inc 子宮障害を処置するためのクロストリジウム神経毒
US10076557B2 (en) 2003-12-09 2018-09-18 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8530410B2 (en) 2004-04-02 2013-09-10 Allergan, Inc. Method for treating a keloid with a botulinum toxin
US7709440B2 (en) 2004-09-23 2010-05-04 Toxcure, Inc. Treating neoplasms with neurotoxin
US8343929B2 (en) 2004-09-23 2013-01-01 Toxcure, Inc. Treating neoplasms with neurotoxin
US8435951B2 (en) 2004-09-23 2013-05-07 Toxcure, Inc. Treating neoplasms with neurotoxin
US10466245B2 (en) 2008-02-20 2019-11-05 The Secretary Of State For Health Covalently linked thermostable kinase for decontamination process validation
WO2010055358A1 (fr) 2008-11-17 2010-05-20 Syntaxin Limited Suppression de cancers
EP2664343A3 (fr) * 2008-11-17 2014-04-02 Syntaxin Limited Suppression du cancer
EP3241560A1 (fr) * 2008-11-17 2017-11-08 Ipsen Bioinnovation Limited Suppression du cancer
US10113159B2 (en) 2008-11-17 2018-10-30 Ipsen Bioinnovation Limited Suppression of cancer
RU2464937C1 (ru) * 2011-05-17 2012-10-27 Федеральное государственное учреждение "Санкт-Петербургский научно-исследовательский институт уха, горла, носа и речи" Министерства здравоохранения и социального развития России (СПб НИИ ЛОР МИНЗДРАВСОЦРАЗВИТИЯ РОССИИ) Способ удаления параганглиомы латерального основания черепа отиатрической формы
RU2615119C1 (ru) * 2016-05-23 2017-04-03 государственное бюджетное образовательное учреждение высшего профессионального образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ хирургического лечения тимпанального гломуса
RU2769917C1 (ru) * 2021-02-24 2022-04-08 федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ хирургического лечения объемных образований среднего уха

Also Published As

Publication number Publication date
TWI300717B (en) 2008-09-11
AU2001276005A1 (en) 2002-02-13
AR030104A1 (es) 2003-08-13

Similar Documents

Publication Publication Date Title
US6139845A (en) Method for treating cancer with a neurotoxin
US6716427B1 (en) Method for treating hypocalcemia
US6974793B2 (en) Method for treating primary hyperparathyroid disorders
CA2768008C (fr) Neurotoxines clostridiales utilisees dans le traitement des troubles uterins
US6358513B1 (en) Method for treating Hashimoto's thyroiditis
CA2397030C (fr) Procedes de traitement de troubles pancreatiques
EP1492561B1 (fr) Methodes de traitement de troubles des glandes mammaires
PT1272207E (pt) Método de tratamento de dor por administração periférica de uma neurotoxina
US6773711B2 (en) Botulinum toxin therapy for Hashimoto's thyroiditis
WO2002009743A1 (fr) Methode de traitement d'un neoplasme
US6821520B2 (en) Clostridial toxin therapy for Hashimoto's thyroiditis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP